HBIO - Harvard Bioscience Inc. Long-Term Liabilities to Capital

Harvard Bioscience creates a fundamental basis for biomedical research by offering global laboratories a unique range of equipment. The integration of software and precision dispensers forms a closed ecosystem that increases switching costs for customers. The long-term debt-to-equity ratio visualizes financial stability, where 5.92 determines the current status of the parameter. The supply of electrophysiology systems ensures stability, while AI modules are being prepared for scaling.

This indicator assesses long-term financial stability through the ratio of liabilities with a maturity of over one year to equity. The metric determines the business's degree of dependence on borrowed funds and the risk of default in the event of declining capitalization. By analyzing the long-term debt-to-equity ratio, one can evaluate the impact of the credit load on the procurement of components from external suppliers. For Harvard Bioscience (HBIO), the leverage balance is critical for maintaining precision assembly at its own plants. The stability of this indicator guarantees investors capital protection against excessive financial risks.